The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Future applications of copper-64-labeled daratumumab PET/CT in MM
Fluoro-deoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM), however intracellular FDG uptake can be seen in both malignant and non-malignant cells, resulting in limited sensitivity and specificity. Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, outlines the various possible ways to make use of the Copper-64-labeled daratumumab PET/CT, that showed improved sensitivity when compared with FDG PET/CT (NCT03311828). Dr Krishnan explains this imaging technique could be used in patients with smoldering myeloma and possibly as a way of seeing if patients will respond to daratumumab therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
